IGM Biosciences (IGMS) Competitors

IGM Biosciences (NASDAQ:IGMS) and Terns Pharmaceuticals (NASDAQ:TERN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, community ranking, profitability, valuation, risk, earnings, media sentiment and dividends.

Does the MarketBeat Community believe in IGMS or TERN?

IGM Biosciences received 30 more outperform votes than Terns Pharmaceuticals when rated by MarketBeat users. However, 59.15% of users gave Terns Pharmaceuticals an outperform vote while only 47.68% of users gave IGM Biosciences an outperform vote.

Company	Underperform	Outperform
IGM Biosciences	Outperform Votes 72 47.68%	Underperform Votes 79 52.32%
Terns Pharmaceuticals	Outperform Votes 42 59.15%	Underperform Votes 29 40.85%

Which has more risk & volatility, IGMS or TERN?

IGM Biosciences has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500. Comparatively, Terns Pharmaceuticals has a beta of -0.3, suggesting that its share price is 130% less volatile than the S&P 500.

Does the media prefer IGMS or TERN?

In the previous week, Terns Pharmaceuticals had 8 more articles in the media than IGM Biosciences. MarketBeat recorded 11 mentions for Terns Pharmaceuticals and 3 mentions for IGM Biosciences. Terns Pharmaceuticals' average media sentiment score of 0.58 beat IGM Biosciences' score of -0.30 indicating that Terns Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IGM Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Terns Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer IGMS or TERN?

IGM Biosciences currently has a consensus price target of $5.50, indicating a potential upside of 336.51%. Terns Pharmaceuticals has a consensus price target of $18.30, indicating a potential upside of 451.20%. Given Terns Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Terns Pharmaceuticals is more favorable than IGM Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IGM Biosciences	1 Sell rating(s)	9 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.90
Terns Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Is IGMS or TERN more profitable?

Terns Pharmaceuticals has a net margin of 0.00% compared to IGM Biosciences' net margin of -7,534.03%. Terns Pharmaceuticals' return on equity of -32.76% beat IGM Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IGM Biosciences	-7,534.03%	-155.42%	-61.04%
Terns Pharmaceuticals	N/A	-32.76%	-31.33%

Do institutionals & insiders have more ownership in IGMS or TERN?

42.8% of IGM Biosciences shares are held by institutional investors. Comparatively, 98.3% of Terns Pharmaceuticals shares are held by institutional investors. 57.0% of IGM Biosciences shares are held by insiders. Comparatively, 15.1% of Terns Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Which has higher earnings and valuation, IGMS or TERN?

Terns Pharmaceuticals has lower revenue, but higher earnings than IGM Biosciences. Terns Pharmaceuticals is trading at a lower price-to-earnings ratio than IGM Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IGM Biosciences	$2.68M	28.11	-$246.42M	-$3.24	-0.39
Terns Pharmaceuticals	N/A	N/A	-$90.21M	-$1.18	-2.81

Summary

Terns Pharmaceuticals beats IGM Biosciences on 12 of the 17 factors compared between the two stocks.